AAAAAA

   
Results: 1-14 |
Results: 14
FACTOR VIIA IS ELEVATED BY FACTOR-V-LEIDEN
Authors: VANOERLE R WAALE W VANPAMPUS L LINDHOUT T PHILIPPOU H LANE DA HAMULYAK K
Citation: R. Vanoerle et al., FACTOR VIIA IS ELEVATED BY FACTOR-V-LEIDEN, Thrombosis and haemostasis, 1997, pp. 55-55
INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND COAGULATION IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS
Authors: LEURS PB VANOERLE R WOLFFENBUTTEL BHR HAMULYAK K
Citation: Pb. Leurs et al., INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND COAGULATION IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS, Thrombosis and haemostasis, 77(3), 1997, pp. 472-476
ORAL-CONTRACEPTIVES AND VENOUS THROMBOSIS - DIFFERENT SENSITIVITIES TO ACTIVATED PROTEIN-C IN WOMEN USING 2ND-GENERATION AND 3RD-GENERATIONORAL-CONTRACEPTIVES
Authors: ROSING J TANS G NICOLAES GAF THOMASSEN MCLGD VANOERLE R VANDERPLOEG PMEN HEIJNEN P HAMULYAK K HEMKER HC
Citation: J. Rosing et al., ORAL-CONTRACEPTIVES AND VENOUS THROMBOSIS - DIFFERENT SENSITIVITIES TO ACTIVATED PROTEIN-C IN WOMEN USING 2ND-GENERATION AND 3RD-GENERATIONORAL-CONTRACEPTIVES, British Journal of Haematology, 97(1), 1997, pp. 233-238
THE CLINICAL-APPLICATION OF A NEW SPECIFIC FUNCTIONAL ASSAY TO DETECTTHE FACTOR-V-LEIDEN MUTATION ASSOCIATED WITH ACTIVATED PROTEIN-C RESISTANCE
Authors: VANOERLE R VANPAMPUS L TANS G ROSING J HAMULYAK K
Citation: R. Vanoerle et al., THE CLINICAL-APPLICATION OF A NEW SPECIFIC FUNCTIONAL ASSAY TO DETECTTHE FACTOR-V-LEIDEN MUTATION ASSOCIATED WITH ACTIVATED PROTEIN-C RESISTANCE, American journal of clinical pathology, 107(5), 1997, pp. 521-526
A PROTHROMBINASE-BASED ASSAY FOR DETECTION OF RESISTANCE TO ACTIVATEDPROTEIN-C
Authors: NICOLAES GAF THOMASSEN MCLGD VANOERLE R HAMULYAK K HEMKER HC TANS G ROSING J
Citation: Gaf. Nicolaes et al., A PROTHROMBINASE-BASED ASSAY FOR DETECTION OF RESISTANCE TO ACTIVATEDPROTEIN-C, Thrombosis and haemostasis, 76(3), 1996, pp. 404-410
INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ACTIVITY AND COAGULATION IN IDDM PATIENTS
Authors: LEURS PB VANOERLE R WOLFFENBUTTEL BHR HAMULYAK K
Citation: Pb. Leurs et al., INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ACTIVITY AND COAGULATION IN IDDM PATIENTS, Diabetologia, 39, 1996, pp. 898-898
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN NORMAL, IGT, AND NIDDM SUBJECTS
Authors: WOLFFENBUTTEL BHR STOLK RP VANOERLE R HAMULYAK K GROBBEE DE LEURS PB
Citation: Bhr. Wolffenbuttel et al., TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN NORMAL, IGT, AND NIDDM SUBJECTS, Diabetologia, 39, 1996, pp. 899-899
THE VALUE OF EUGLOBULIN CLOT LYSIS TIMES IN POST VENOUS OCCLUSION STABILYTE PLASMAS IN PATIENTS WITH IDIOPATHIC DVT
Authors: PERNOT C VANOERLE R METZDASSEN E HAMULYAK K
Citation: C. Pernot et al., THE VALUE OF EUGLOBULIN CLOT LYSIS TIMES IN POST VENOUS OCCLUSION STABILYTE PLASMAS IN PATIENTS WITH IDIOPATHIC DVT, Thrombosis and haemostasis, 73(6), 1995, pp. 1143-1143
D-GLUCOSE INCREASES TISSUE FACTOR PATHWAY INHIBITOR (TFPI) RELEASE FROM CULTURED ENDOTHELIAL-CELLS (EC) AFTER HEPARIN STIMULATION
Authors: LEURS PB VANOERLE R WOLFFENBUTTEL BHR HAMULYAK K
Citation: Pb. Leurs et al., D-GLUCOSE INCREASES TISSUE FACTOR PATHWAY INHIBITOR (TFPI) RELEASE FROM CULTURED ENDOTHELIAL-CELLS (EC) AFTER HEPARIN STIMULATION, Thrombosis and haemostasis, 73(6), 1995, pp. 1261-1261
HEPARIN-INDUCED RELEASE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FROM HUMAN ENDOTHELIAL HYBRID-CELLS
Authors: VANOERLE R LEURS PB LINDHOUT T HAMULYAK K
Citation: R. Vanoerle et al., HEPARIN-INDUCED RELEASE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FROM HUMAN ENDOTHELIAL HYBRID-CELLS, Thrombosis and haemostasis, 73(6), 1995, pp. 1262-1262
TISSUE FACTOR PATHWAY INHIBITOR IN IDDM PATIENTS WITH AND WITHOUT MICROVASCULAR AND OR MACROVASCULAR COMPLICATIONS/
Authors: LEURS PB VANOERLE R HAMULYAK K WOLFFENBUTTEL BHR
Citation: Pb. Leurs et al., TISSUE FACTOR PATHWAY INHIBITOR IN IDDM PATIENTS WITH AND WITHOUT MICROVASCULAR AND OR MACROVASCULAR COMPLICATIONS/, Diabetologia, 38, 1995, pp. 53-53
TISSUE FACTOR PATHWAY INHIBITOR ACTIVITY IN PATIENTS WITH IDDM
Authors: LEURS PB VANOERLE R HAMULYAK K WOLFFENBUTTEL BHR
Citation: Pb. Leurs et al., TISSUE FACTOR PATHWAY INHIBITOR ACTIVITY IN PATIENTS WITH IDDM, Diabetes, 44(1), 1995, pp. 80-84
THE ANTICOAGULANT ACTIVITY OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN PLASMA ASSESSED BY AN AUTOMATED-ASSAY ON AN ACL-300R COAGULATION APPARATUS
Authors: VANOERLE R LEURS P LINDHOUT T NORDFANG O HAMULYAK K
Citation: R. Vanoerle et al., THE ANTICOAGULANT ACTIVITY OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN PLASMA ASSESSED BY AN AUTOMATED-ASSAY ON AN ACL-300R COAGULATION APPARATUS, Thrombosis and haemostasis, 69(6), 1993, pp. 1119-1119
A NOVEL AUTOMATED FACTOR-VA ASSAY BASED ON THE GENERATION OF PROTHROMBIN CONVERTING ACTIVITY
Authors: VANOERLE R LINDHOUT T HAMULYAK K
Citation: R. Vanoerle et al., A NOVEL AUTOMATED FACTOR-VA ASSAY BASED ON THE GENERATION OF PROTHROMBIN CONVERTING ACTIVITY, Thrombosis and haemostasis, 69(6), 1993, pp. 1120-1120
Risultati: 1-14 |